Interferon lambda concentrations in nasal lining fluid fell in or above the predicted therapeutic range with a nasally ...

N 6-methyladenosine (m 6 A) is the most extensive studied RNA modification across various species, and the important effect of m 6 A modification in immune system has been revealed in distinct ...

The mRNA therapeutics market offers key opportunities in developing vaccines and treatments for chronic and infectious diseases, driven by successful clinical trials and increased government and ...

In the fast-evolving field of medical science, a new artificial intelligence model may be about to change the way mRNA-based drugs and vaccines are designed. Developed through a collaboration between ...

Targeting mRNA expression presents a promising approach in the treatment of haploinsufficiency disorders, offering a new avenue for therapeutic intervention. While gene expression changes are commonly ...

A KAIST research team led by Professor Won Do Heo (Department of Biological Sciences) has developed an optogenetic platform, RELISR (REversible LIght-induced Store and Release), that enables precise ...

The same groundbreaking technology that enabled rapid COVID-19 vaccine development is now poised to revolutionize medicine in ways that seemed impossible just a few years ago. Messenger RNA vaccines ...

Wacker Biotech, a CDMO, began a strategic collaboration with Boston-based RNAV8 Bio aimed at progressing the development and production of mRNA-based advanced therapies for the biopharma industry.

A KAIST research team led by Professor Won Do Heo (Department of Biological Sciences) has developed an optogenetic platform, RELISR (REversible LIght-induced Store and Release), that enables precise ...